Industry Insights

Cell and gene therapy trends for US equity investors

  • Public Equity
  • Healthcare
  • North America

We have brought together some of Third Bridge Forum’s most topical and popular Interviews among US equity investors in H1 2023 across the healthcare, TMT, financials, consumer and IME sectors. Starting with healthcare, this piece highlights cell and gene therapy manufacturing developments, gene therapy delivery methods, and exclusive insights on contract development and manufacturing organisation (CDMO) Catalent.

Read More

Submit your email address for full access to our Research content.